A new drug, flecainide, has been registered
Mir-Pharm announces the successful registration and entry into civil circulation of a new antiarrhythmic agent – Flecainide.
Moscow, April 2024
Flecainide is an antiarrhythmic agent of IC class according to the Vaughan-Williams classification. It binds to the sodium channels of cardiomyocyte membranes, causing potent slowing of cardiac impulse conduction and suppression of spontaneous premature ventricular contractions.
Flecainide firmly binds to fast sodium channels and thus slows the rate of depolarisation and reduces conduction in atria, atrioventricular node, ventricles and Purkinje fibres. The most pronounced effect is observed in Purkinje fibres.
Note:
The press release contains information about prescription medications. Use of this information for preparation of publications must be made in accordance with the legislation of the Russian Federation on advertising (including but not limited to Art. 24 of the Federal Law of 13.03.2006 No. 38-FL "On Advertising"), according to which, in particular, advertising of prescription drugs is allowed only in places of medical or pharmaceutical exhibitions, workshops, conferences and other similar events as well as in specialized print media intended for medical and pharmaceutical workers. Failure to comply with the above requirements (namely, mentioning the name of the drug, placing an image of the package or its elements in the media other than specialized print publications intended for medical and pharmaceutical workers) shall entail administrative liability.